Search results
Showing 1366 to 1380 of 8929 results
Evidence-based recommendations on naltrexone (Nalorex) for managing opioid dependence in adults.
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA859
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.
NICE is unable to make a recommendation on vedolizumab (Entyvio) for treating chronic refractory pouchitis after surgery for ulcerative colitis in adults. This is because Takeda did not provide an evidence submission.
Show all sections
Sections for TA826
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its evidence submission.
Show all sections
Sections for TA1068
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.